Skip to main content

Table 1 Clinical features of the population under study

From: Novel equation to determine the hepatic triglyceride concentration in humans by MRI: diagnosis and monitoring of NAFLD in obese patients before and after bariatric surgery

Clinical characteristics Control group (number = 32) Obese group (number = 97) Pvalue Overall (number = 129)
Age (years) 60.9 ± 11.5 46.7 ± 13.4 <0.0001 50.2 ± 14.3
Weight (Kg) 71.9 ± 13.6 120.7 ± 26.3 <0.0001 108.7 ± 31.8
BMI (Kg/m2) 26 ± 4.5 44.6 ± 7.9 <0.0001 40 ± 10.8
Associated diseases and treatments     
Diabetes 5 (15.63%) 28 (28.86%) N.S. 33 (25.58%)
Dyslipidemia 10 (31.25%) 36 (37.11%) 0.054 46 (35.66%)
Obstructive sleep apnea 1 (3.1%) 32 (33%) <0.001 33 (25.6%)
Contraceptive 1 (3.1%) 3 (3.1%) N.S. 4 (3.1%)
Statin 3 (9.3%) 17 (17.5%) N.S. 20 (15.5%)
Immunesuppresive 1 (3.1%) 5 (5.15%) N.S. 6 (4.65%)
Antidepressant 2 (6.2%) 11(11.34%) N.S. 13 (10.07%)
Nifedipine 0 (0%) 10 (10.3%) N.S. 10 (7.75%)
Hormone 1 (3.1%) 6 (6.18%) N.S. 7 (5.42%)
Paracetamol 2 (6.2%) 7 (7.21%) N.S. 9 (6.97%)
Serological assessments     
AST (U/L) 26.8 ± 12.9 24.7 ± 12.9 N.S. 25.2 ± 12.9
ALT (U/L) 31.8 ± 20 32.7 ± 21.8 N.S. 32.4 ± 21.3
GGT (U/L) 53 ± 46.4 35.6 ± 29.3 N.S. 40.2 ± 35.3
ALP (U/L) 99.9 ± 48.5 71.6 ± 22.4 <0.01 79.7 ± 34.3
Triglycerides (mg/dL) 106.9 ± 54.1 163.3 ± 154.8 <0.01 148.5 ± 137.8
Cholesterol (mg/dL) 190.6 ± 54.1 200.8 ± 42.6 N.S. 198.2 ± 45.9
Liver triglyceride content - Biochemical assay (mg/g) 33.3 ± 28.3 94.5 ± 57.1 <0.0001 79.3 ± 57.8
  1. ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; GGT, gamma glutamyl transpeptidase.